With its vaccine schedule, “Denmark has made a values choice to accept preventable hospitalizations and illnesses that other ...

BioMarin's new CEO had promised Wall Street there would be deals, and with Amicus, it has one the market likes.

Nine drugmakers are set to unveil deals with the Trump administration to lower the prices of some of their drugs, marking the ...

A vaccine adviser at the CDC with ties to health secretary Robert F. Kennedy Jr. is being given a new portfolio overseeing ...

It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared ...

BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...

WASHINGTON — Brand drugmakers have agreed to donate bulk ingredients to a national stockpile as part of deals with the Trump ...

The Trump administration has announced sweeping policies that, if enacted, could effectively end gender-affirming care for ...

UnitedHealth Group said Friday that the consultants it hired to audit its operations found they’re not only “robust,” but ...

BioMarin said it is acquiring Amicus Therapeutics, maker of rare-disease drugs, for $4.8 billion. A new FDA program meant to ...

Two government officials told STAT that the White House has been involved in final decisions about the FDA's new priority ...

The Trump administration intends to make its most forceful attempt yet at restricting gender-affirming care for transgender ...